1 Biotech Steamrolling the Competition

Editor's Note: Overall Survival was reached in the phase 3 trial and favored Imbruvica.

Pharmacyclics  and Johnson & Johnson's  Imbruvica has had a great roll-out thus far.

And the celebration may not be over yet. 

New data indicate that Imbruvica embarrassed the competition, GlaxoSmithKline's Arzerra. Imbruvica was associated with almost an 80% decline in the risk of cancer progression or death compared to Arzerra in a head-to-head phase 3 trial. And the safety profiles of the drugs were fairly similar.

But, there are some threats on the horizon, including AbbVie's ABT-199.

In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson discuss the data and what investors need to know about Imbruvica.

Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The article 1 Biotech Steamrolling the Competition originally appeared on Fool.com.

David Williamson owns shares of Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story